Anavex Life Sciences Corp (AVXL)

[boi568]

What I got from the call was related to biomarkers for the 2b/3:

1. The company is going to play the beneficial effect on brain loss -- as they should.

2. We learned that blarcamesine bested the MABs in the plaque biomarker. That was news. There is a minor caveat regarding blood plasma levels versus CSF levels, but it does not appear significant.

3. Anavex will argue for the restorative effects found in its genomic study to be taken into account.

This was a better than usual presentation.